Disc Medicine Inc., a clinical-stage biopharmaceutical company, has announced a positive pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA). The meeting discussed the planned NDA submission for their drug bitopertin, intended for the treatment of Erythropoietic Protoporphyria $(EPP.UK)$. The company has confirmed alignment with the FDA on the expected timing and content of the NDA submission, which is slated for October 2025. This progress indicates Disc Medicine's preparation for its potential first product launch, aiming to utilize the FDA's accelerated approval pathway based on existing data.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.